← Back to patent-cliff list
Pafolacianine Sodium
Tier C — Watch / tradePafolacianine Sodium
On Target Laboratories Inc
Originator
2021
First approval
-
Expiry (public)
No sales data
Peak sales
In vivo diagnostic
Type
Targets：FOLR1
Brand：Cytalux
Indications (approved)：Lung cancer, Ovarian cancer
Regional status
US
Approved
2021-11-29
EU
Phase II
2017-05-04
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Pafolacianine Sodium?
Approved indications include: Lung cancer, Ovarian cancer.
When does the Pafolacianine Sodium patent expire?
No public expiry year is available for Pafolacianine Sodium yet; this page updates once verified.
How do I get a quote for Pafolacianine Sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27